生命科学资讯

After years of dispute with FDA, Vanda will get a public hearing for jet lag drug

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

FDA explains how some copycat drugs can still win three years of exclusivity

EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up

Theravance ends R&D, lays off 50% of workers after Phase 3 fail

Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

CMS' Chris Klomp on what it will take for AI to succeed in healthcare

Esperion to buy Corstasis and its nasal spray for edema for $75M upfront

Two more members added to ACIP ahead of March meeting

United Therapeutics to take pulmonary hypertension drug to FDA for approval

Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC

Roche gets third pivotal win with MS drug, but liver signal could be a problem

FDA lifts hold on second Intellia Phase 3 gene editing trial

Candid to go public via reverse merger with Rallybio

Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover

UniQure says FDA prefers randomized trial for Huntington's treatment

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima